FSC231 (50 μM) blocks binding between GluR2 and PICK1 in COS7 cells[2].
FSC231 (78.40 μg/kg in total, daily, seven times, i.p., 3 h before Paclitaxel) alleviates the Paclitaxel ‐induced neuralgia of rats[1].
FSC231 (39.2μg/kg/day, i.p., for 4 weeks) inhibits the development of diabetic cardiomyopathy in rats by inhibiting ROS generation and apoptosis partly via PICK1/eNOS/cGMP pathway[3].
References:
[1]. Zhang X, et al. FSC231 alleviates paclitaxel-induced neuralgia by inhibiting the interactions between PICK1 and GluA2 and activates GSK-3β and ERK1/2. Brain Behav. 2021 Nov;11(11):e2380.
[2]. Thorsen TS, et al. Identification of a small-molecule inhibitor of the PICK1 PDZ domain that inhibits hippocampal LTP and LTD. Proc Natl Acad Sci U S A. 2010 Jan 5;107(1):413-8.
[3]. Cai Fei, et al. GW27-e1146 PICK1 inhibition restores myocardial injury by suppressing reactive oxygen species generation and apoptosis in diabetic rats. J Am Coll Cardiol. 2016 Oct, 68 (16_Supplement) C67.